Contineum Therapeutics (Contineum Therapeutics) Short-Term Capital Lease Obligation : $0.47 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Short-Term Capital Lease Obligation?

Contineum Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.47 Mil.

Contineum Therapeutics's quarterly Short-Term Capital Lease Obligation declined from Sep. 2023 ($1.12 Mil) to Dec. 2023 ($0.46 Mil) but then increased from Dec. 2023 ($0.46 Mil) to Mar. 2024 ($0.47 Mil).

Contineum Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($1.11 Mil) but then declined from Dec. 2022 ($1.11 Mil) to Dec. 2023 ($0.46 Mil).

Contineum Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Contineum Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Short-Term Capital Lease Obligation Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

1.11

0.46

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial			1.11	-	1.12	0.46	0.47

Contineum Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Contineum Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024